PHARMACEUTICS LL EXAM 2 PRACTICE (SAMPLE)

STUDY GUIDE

SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://ceutics2exam2.examzify.com

Table of Contents

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

1. Shelf-life is the period during which a DS and DP remains within the approved specifications, provided that it is stored under the approved conditions in the approved packaging.

A. True

B. False

C. It refers to the surface area of packaging

D. It refers to the cost of packaging

2. A 45-year-old mechanically ventilated patient receives propofol 200 mg/h in a 10 mg/mL formulation in a 10% lipid emulsion. How many calories per day does this provide?

A. 100

B. 144

C. 264

D. 528

3. Which statement about powder weight and compression in wet granulation is correct?

A. Heavier powder makes compression harder

B. Heavier powder makes compression easier

C. Powder weight has no effect

D. Heavier powder prevents granulation

4. What excipient is commonly found in chewable tablets?

A. Sorbitol

B. Lactose

C. Microcrystalline cellulose

D. Mannitol

5. Which dissolution apparatus is best for poorly soluble or controlled-release forms?

A. Apparatus I (Basket) for tablets/granules

B. Apparatus II (Paddle) for tablets/capsules

C. Apparatus III (Reciprocating Cylinder) for poorly soluble or controlled-release forms

D. Apparatus IV (Flow-through) for insoluble or highly permeable compounds and non-traditional dosage forms

6. Dissolution testing is related to bioavailability because it measures what?

A. The color and odor of a dissolution medium.

B. The taste of the dosage form.

C. The rate and extent of drug release; dissolution correlates with bioavailability and batch-to-batch consistency.

D. Disintegration time alone determines bioavailability.

7. What is an advantage of wet granulation?

A. Improves flow properties

B. Increases moisture sensitivity to unstable drugs

C. Eliminates the need for drying

D. Reduces compressional properties

8. Which set of ICH guidelines supports a risk-based, science-led approach with regulatory flexibility within a defined design space?

A. The guidelines are not applicable to design space.

B. Q8, Q9, Q10, and Q11 collectively support this approach.

C. Q2 and Q3 only address design space.

D. Q5 and Q6 only address development.

9. A suspension is composed of which of the following?

A. Solid in liquid

B. Liquid in gas

C. Gas in liquid

D. Liquid in liquid

10. Direct compression can have uniformity problems.

A. False

B. True

C. Not sure

D. It depends on the batch

Answers

1. A
2. D
3. B
4. D
5. C
6. D
7. A
8. B
9. A
10. B

Explanations

1. Shelf-life is the period during which a DS and DP remains within the approved specifications, provided that it is stored under the approved conditions in the approved packaging.

A. True

B. False

C. It refers to the surface area of packaging

D. It refers to the cost of packaging

Shelf-life is defined by how long the drug substance and the drug product stay within their approved quality specifications when stored under the specified conditions in the approved packaging. This concept hinges on stability data: the product is tested over time under defined temperatures, humidity, light, and packaging to ensure it continues to meet identity, potency, purity, and safety limits. If these criteria remain met, the product is considered suitable for use for that period; once they shift outside the specifications, the product is no longer within its shelf-life. The packaging and storage conditions are integral because they influence the rate of degradation. Packaging that provides adequate protection and storage that keeps conditions constant help maintain quality for the stated shelf-life. Choices referencing surface area of packaging or packaging cost are not related to how long the product remains within specifications, so they don't define shelf-life. Therefore, the statement is true.

2. A 45-year-old mechanically ventilated patient receives propofol 200 mg/h in a 10 mg/mL formulation in a 10% lipid emulsion. How many calories per day does this provide?

A. 100

B. 144

C. 264

D. 528

Propofol is given in a lipid emulsion, so the calories come from the fat in that emulsion. Convert the dose to volume: 200 mg/h at 10 mg/mL equals 20 mL/h. A 10% lipid emulsion provides about 1.1 kcal per mL, so hourly calories are 20 mL/h × 1.1 kcal/mL = 22 kcal/h. Over 24 hours, 22 × 24 = 528 kcal/day.

3. Which statement about powder weight and compression in wet granulation is correct?

A. Heavier powder makes compression harder

B. Heavier powder makes compression easier

C. Powder weight has no effect

D. Heavier powder prevents granulation

The main idea is how the mass per unit volume of the powder (bulk density) influences how a powder compacts during wet granulation. When powder is heavier, it has higher bulk density, meaning more material sits in the same die volume. That closer packing and higher initial solid fraction allow particles to come into contact and deform or bond more readily under the same compression; moisture from wet granulation also helps form capillary bridges between particles, strengthening the compact. So, for a given compression force, a heavier powder generally densifies and strengthens more easily, making compression easier. The idea that heavier powder would make compression harder would require less contact or more friction, which isn't typical for higher bulk density. Saying powder weight has no effect ignores the role of packing density in compression. And claiming heavier powder prevents granulation isn't accurate—granulation depends on moisture, binder, and process conditions, not simply on powder weight.

4. What excipient is commonly found in chewable tablets?

A. Sorbitol

B. Lactose

C. Microcrystalline cellulose

D. Mannitol

Chewable tablets rely on excipients that provide sweetness and a pleasant mouthfeel, since the dosage form is designed to be chewed rather than swallowed with water. Mannitol fits this role well: it is a sugar alcohol that delivers non-cariogenic sweetness and a cool, smooth mouthfeel. It also doubles as a diluent and compresses well, helping form a robust chewable tablet. Among alternatives, sorbitol is another sweetener used in chewables, but mannitol is favored for its better mouthfeel and lower hygroscopicity, which aids stability and handling. Lactose can serve as a filler in many tablets but is less ideal for chewables due to potential lactose intolerance issues and a lack of the distinctive mouthfeel mannitol provides. Microcrystalline cellulose mainly offers structure as a filler and binder and does not contribute significant sweetness or mouthfeel. Therefore, mannitol is commonly found in chewable tablets.

5. Which dissolution apparatus is best for poorly soluble or controlled-release forms?

A. Apparatus I (Basket) for tablets/granules

B. Apparatus II (Paddle) for tablets/capsules

C. Apparatus III (Reciprocating Cylinder) for poorly soluble or controlled-release forms

D. Apparatus IV (Flow-through) for insoluble or highly permeable compounds and non-traditional dosage forms

Dissolution effectiveness hinges on how well the surrounding fluid can contact the solid surface and remove dissolved drug, especially when solubility is limited or the release is controlled. The reciprocating cylinder setup provides a carefully controlled hydrodynamic environment: the cylinder moves up and down in the dissolution medium, creating a dynamic flow around the dosage form that reduces the stagnant boundary layer and delivers fresh solvent consistently. This combination helps reveal the true dissolution behavior of poorly soluble drugs and, at the same time, lets the release mechanism of a controlled release form proceed without being overly disrupted by aggressive mixing. In practice, this means you get more representative, reproducible dissolution data for forms that are hard to dissolve or designed to release drug over time. The other apparatus have their uses—for example, baskets and paddles are common for conventional tablets and capsules, but their agitation can risk damaging coatings or displacing non-disintegrating forms; the flow through setup is excellent for truly solubility limited scenarios and nontraditional dosage forms, but it's more complex and may not mimic the specific hydrodynamics that CR or poorly soluble systems benefit from as effectively. So, the reciprocating cylinder is the best match for poorly soluble or controlled release forms.

6. Dissolution testing is related to bioavailability because it measures what?

A. The color and odor of a dissolution medium.

B. The taste of the dosage form.

C. The rate and extent of drug release; dissolution correlates with bioavailability and batch-to-batch consistency.

D. Disintegration time alone determines bioavailability.

Dissolution testing relates to bioavailability because it directly measures how quickly and how much of the drug leaves the dosage form and goes into solution under conditions like the GI environment. Absorption depends on the drug being dissolved; if it doesn't dissolve well, little of it can reach systemic circulation, so dissolution rate and extent largely determine the amount that can be absorbed over time. That's why dissolution data are used to predict in vivo bioavailability and to ensure batch-to-batch consistency. Disintegration is a separate step that just breaks the tablet apart; even fast disintegration won't guarantee good absorption if the drug doesn't dissolve readily. Color, odor, or taste are not indicators of bioavailability.

7. What is an advantage of wet granulation?

A. Improves flow properties

B. Increases moisture sensitivity to unstable drugs

C. Eliminates the need for drying

D. Reduces compressional properties

Wet granulation forms granules by adding a binder liquid to powder, creating larger, more uniform particles. This reduces interparticle friction and cohesive forces, so the material flows much more readily from hoppers and into dies, leading to smoother and more uniform die filling and better content uniformity in the final tablet. That improvement in flow properties is the key advantage here, because consistent filling and dosing rely on good flow. The other statements don't fit as advantages. Introducing moisture in the process can pose stability risks for moisture-sensitive drugs, and the method actually requires a drying step after granulation, not eliminates it. As for compressional behavior, granulation typically improves tabletability rather than reducing it, so a claim that it reduces compressional properties isn't accurate.

8. Which set of ICH guidelines supports a risk-based, science-led approach with regulatory flexibility within a defined design space?

A. The guidelines are not applicable to design space.

B. Q8, Q9, Q10, and Q11 collectively support this approach.

C. Q2 and Q3 only address design space.

D. Q5 and Q6 only address development.

This item tests understanding of how ICH quality by design and risk-based thinking are integrated across guidelines to enable regulatory flexibility within a defined design space. The set of guidelines that collectively supports this approach includes Q8, which introduces QbD concepts, design space, and building quality into development through scientific understanding; Q9, which provides a formal risk management framework to identify, assess, and control risks throughout development and manufacturing; Q10, which establishes a Pharmaceutical Quality System and a lifecycle approach that enables knowledge management and change control aligned with the design space; and Q11, which extends these principles to development and manufacture of drug substances and products, reinforcing how changes are managed through robust knowledge within the design space. Together, they articulate a risk-based, science-led path with regulatory flexibility when changes stay within the defined design space and are supported by a strong knowledge base. The other options misstate the scope or omit the guidelines that explicitly enable design space and risk-based flexibility.

9. A suspension is composed of which of the following?

A. Solid in liquid

B. Liquid in gas

C. Gas in liquid

D. Liquid in liquid

Suspensions are heterogeneous mixtures where solid particles are dispersed in a liquid. The particles remain as distinct solids and are not fully dissolved, so the mixture appears cloudy and the particles will settle to the bottom over time. This solid-in-liquid arrangement defines a suspension, and stirring can keep the particles suspended temporarily, but without agitation they settle out. In contrast, liquid in gas would be liquid droplets in air (an aerosol), liquid in liquid would be an emulsion, and gas in liquid would be gas bubbles in a liquid, not solid dispersed in a liquid. So the composition is solid dispersed in a liquid.

10. Direct compression can have uniformity problems.

A. False

B. True

C. Not sure

D. It depends on the batch

Direct compression relies on forming tablets from a blend of drug and excipients without a granulation step, so achieving uniform distribution of the drug is highly dependent on powder properties and blending performance. If the API and the excipients differ in particle size, density, or cohesiveness, the powder can segregate during mixing, handling, or die-filling, leading to some tablets with more drug and others with less. Without granulation to promote a more uniform matrix, the blend's flow and compressibility largely determine weight and content uniformity. Moisture, static, and high drug loads can further worsen uniformity. With careful formulation, proper blending, flow aids, and process controls, these issues can be mitigated, but the inherent risk remains, so the statement is true.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://ceutics2exam2.examzify.com

We wish you the very best on your exam journey. You've got this!